- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stephen Rozzo on Regulatory Nature of Tildrakizumab for Psoriasis
Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.
The regulatory nature of tildrakizumab and its administration in office distinguish the drug from other approved biologics for psoriasis, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Transcript
What are the mechanisms of action for tildrakizumab in the treatment of psoriasis and how does the drug compare with other approved biologics?
The mechanism of action of tildrakizumab is not completely known, but it binds interleukin (IL)-23 p19 polypeptide, which is a pro-inflammatory molecule [that] regulates immune responses to inflammation.
It is distinct in the sense that among similar agents, it is administered by dermatologists in their offices. And for that reason, we can be sure that the patients actually get their medication as opposed to other agents administered at home.
There are other mechanisms of action for drugs that bind tumor necrosis factor and inhibit that pro-inflammatory molecule, and others that bind IL-17, a different cytokine that is pro-inflammatory. The distinction with IL-23 is its regulatory nature. In other words, it does not in itself induce inflammation as the other 2 molecules do; it regulates the response to stimuli.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
